FDA requires a fairly high bar in terms of clinical trail evidence - it is definitely not just a formality.
There have been other IF companies who had to abandon their applications at this stage. Munchkin Grassfed Formula from NZ comes to mind.
I'm not expecting this would happen, but they're not going to be waved through just because they already had temporary access.
Ann: Bubs Q2 FY24 Quarterly Activity and Cashflow Statement, page-21
-
- There are more pages in this discussion • 32 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BUB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $115.9M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 13.0¢ | 12.0¢ | $518.0K | 4.145M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 220000 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 927069 | 26 |
View Market Depth
| Last trade - 16.10pm 24/06/2024 (20 minute delay) ? |
| BUB (ASX) Chart |